Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Insys Therapeutics Inc. (NASDAQ: INSY).

Full DD Report for INSY

You must become a subscriber to view this report.


Recent News from (NASDAQ: INSY)

FDA OKs first non-opioid treatment for opioid withdrawal
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: May, 16 2018 16:44
Insys Continues To Tread Water
Insys (INSY) missed on Q1 revenue and earnings. The company's revenue appeared to have stabilized in Q4 2017, growing 3% sequentially. This quarter the company reported revenue of $24 million, down 24% sequentially and 34% Y/Y. Revenue from Susbsys was $24 million, down 35% Y/Y, while Synd...
Source: SeekingAlpha
Date: May, 16 2018 06:05
INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts
PHOENIX, May 15, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today issued the following response to the unsealing of the previously filed Qui Tam compla...
Source: GlobeNewswire
Date: May, 15 2018 12:22
Weekly Cannabis Report: Aurora/MedReleaf, Canopy, Maricann
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis. Weekly Note to Readers The cannabis sector saw its biggest acquisition to-date when Aurora (ACBFF) finally announced the acquisition of MedReleaf (MEDFF) for a h...
Source: SeekingAlpha
Date: May, 15 2018 10:20
Insys Therapeutics' (INSY) CEO Saeed Motahari on Q1 2018 Results - Earnings Call Transcript
Insys Therapeutics (INSY) Q1 2018 Earnings Conference Call May 08, 2018 05:00 PM ET Executives Gus Springmann - IR Saeed Motahari - President and CEO Andrew Long - CFO Steve Sherman - SVP, Regulatory Affairs Analysts Ashley Ryu - RBC Capital Markets Ken Trbovich - Janne...
Source: SeekingAlpha
Date: May, 08 2018 22:02
Insys Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Insys Therapeutics, Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 08 2018 20:07
Insys Therapeutics misses by $0.01, misses on revenue
Insys Therapeutics (NASDAQ: INSY ): Q1 EPS of -$0.19 misses by $0.01 . More news on: Insys Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:13
INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East
PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has agreed to an exclusive license partnership with Lunatus for comme...
Source: GlobeNewswire
Date: May, 08 2018 16:02
INSYS Therapeutics Reports First Quarter 2018 Results
Cannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS ® revenue continue PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization o...
Source: GlobeNewswire
Date: May, 08 2018 16:00
Weekly Cannabis Report: MedReleaf Sell, TGOD IPO, Loblaw Wins
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis. Weekly Note to Readers There are three things that cannabis investors need to know from last week. Fourth-largest Canadian cannabis company MedReleaf is reported...
Source: SeekingAlpha
Date: May, 08 2018 15:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-177.137.347.42947.07492,162
2017-11-275.195.335.335.04772,415
2017-11-245.285.055.295.05514,915
2017-11-225.275.205.305.16395,784
2017-11-215.245.225.405.11675,428

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-25122,327179,15968.2785Short
2018-05-2472,702153,19047.4587Short
2018-05-23102,593367,38927.9249Cover
2018-05-22201,970400,22550.4641Short
2018-05-21234,506373,33262.8143Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INSY.


About Insys Therapeutics Inc. (NASDAQ: INSY)

Logo for Insys Therapeutics Inc. (NASDAQ: INSY)

Not available

 

Contact Information

 

 

Current Management

  • Michael Babich / President, COO
  • Matthew Napoletano / VP, Mkt.
  • Martin K. McCarthy / Controller

Current Share Structure

  • Market Cap: $478,222,430 - 05/11/2018
  • Issue and Outstanding: 69,915,560 - 06/08/2015

 


Recent Filings from (NASDAQ: INSY)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 12 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 01 2018

 

 


Daily Technical Chart for (NASDAQ: INSY)

Daily Technical Chart for (NASDAQ: INSY)


Stay tuned for daily updates and more on (NASDAQ: INSY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: INSY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INSY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of INSY and does not buy, sell, or trade any shares of INSY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/